Wistar Institute Launches the Center for Advanced Therapeutics
The Wistar Institute proudly unveils its new Center for Advanced Therapeutics (CAT), striving to harness innovative science that propels the development of new medications and therapies aimed at enhancing human health. This new center is spearheaded by Paul Lieberman, Ph.D., capitalizing on Wistar’s celebrated research excellence in fields such as cancer, immunology, and infectious diseases.
A Vision for Transformative Healthcare
Reflecting on the significant strides made in combating severe diseases, Dario Altieri, M.D., the President and CEO of Wistar, emphasizes the ongoing urgent requirement for innovation and collaboration. He passionately articulates the necessity for rigorous research, stating, "This can only come from groundbreaking research that Wistar is known for worldwide.” The Center aims to act as a catalyst for multidisciplinary collaboration, effectively translating new disease insights into potential treatments.
Leadership and Expertise
Under Lieberman’s expert leadership, the CAT intends to pinpoint new biomedical research breakthroughs, guiding them toward successful pharmaceutical innovations. Lieberman’s extensive knowledge in studying the Epstein-Barr virus and its cancer implications has shaped the Center’s forward-thinking strategy.
An Innovative Approach to Drug Development
The inception of the Center for Advanced Therapeutics marks a pivotal moment in Wistar’s drug discovery narrative, integrating biology, chemistry, and artificial intelligence to explore new research horizons and foster substantial partnerships across various sectors. This integrative approach will streamline the journey from laboratory research to clinical application, ultimately improving patient care.
Creating Opportunities and Building Teams
The Center will not only advance drug discovery but also create opportunities for Wistar’s researchers to explore novel therapeutic pathways. Over the next two years, the center plans to recruit five principal investigators focused on accelerating the drug development pipeline. Experts in computational chemistry and biology will play a crucial role in identifying crucial biological targets and designing new chemical structures for enhanced cancer and immune disorder treatments.
Collaboration and Future Goals
Wistar’s multidisciplinary team comprises dynamic experts such as Joseph Salvino, Ph.D., who specializes in validating small molecule targets, and Samantha Soldan, Ph.D., who focuses on preclinical research in autoimmune diseases. Additionally, Heather Steinman, Ph.D., MBA, as the Senior Vice President of Business Development, will oversee collaborations with biotech and pharmaceutical firms.
The Center aims to:
- Bridge the divide between chemistry and biology by recruiting computational chemists focused on novel therapeutic designs.
- Utilize artificial intelligence and machine learning in drug discovery and development.
- Enhance multidisciplinary industry collaborations to turn early-stage discoveries into therapeutic realities.
- Expand research into early-stage autoimmune diseases, complementing Wistar’s established expertise in cancer biology.
Significant Funding and Future Expansion
Wistar Institute has been generously funded by a $30 million gift from an anonymous donor, the largest sum in its history, to launch the Center for Advanced Therapeutics. Additionally, the Pew Charitable Trusts has awarded a vital $1 million grant, aiding Wistar in Lieberman’s directorship and the recruitment of essential staff.
Occupying a newly remodeled 12,000 square feet on Wistar’s campus, the CAT signifies substantial progress in Wistar’s ongoing mission to transform healthcare through research. This launch comes on the heels of the first major opening in 2025, the HIV Cure and Viral Diseases Center, which boasts over 25,000 square feet dedicated to research and collaborative spaces.
Conclusion
The Wistar Institute is a prominent player in biomedical research, particularly in cancer studies and vaccine development. Founded in 1892, Wistar stands as America’s first independent nonprofit biomedical research institute, maintaining its Cancer Center designation from the National Cancer Institute since 1972. Its commitment to transitioning research from labs to clinics highlights its dedication to advancing human health and well-being.
Frequently Asked Questions
What is the primary goal of the Center for Advanced Therapeutics?
The Center aims to accelerate the development of new drugs and therapies, enhancing human health.
Who is leading the Center for Advanced Therapeutics?
The Center is led by Paul Lieberman, Ph.D., an expert in cancer research and virus-related diseases.
How will the Center support drug discovery?
The Center will bring together multidisciplinary teams to identify novel therapeutic strategies and enhance collaboration across sectors.
What funding supports the Center?
The Center received a significant $30 million gift and a $1 million grant from the Pew Charitable Trusts.
What facilities are available at the Center?
The CAT occupies 12,000 square feet of renovated space at the Wistar Institute's campus, equipped for advanced research and collaboration.
